Rui Zhang1, Huanjun Wang1, Junyu Zhao1, Jinming Yao1, Hongxia Shang1, Huangao Zhu2, Lin Liao1, Jianjun Dong2. 1. Department of Internal Medicine, Division of Endocrinology, Shandong Provincial Qian Foshan Hospital Jinan 250014, China. 2. Department of Internal Medicine, Division of Endocrinology, Qilu Hospital of Shandong University Jinan 250012, China.
Abstract
CONTEXT: As many studies proved that sodium iodide symporter (NIS) plays a key role in radioactive iodide (RAI) therapy of thyroid cancer, however, a growing number of studies suggests that part of differentiated thyroid carcinomas (DTC) with overexpression of NIS are insensitive to RAI well. OBJECTIVE: The aim of this meta-analysis is to assess the expression of NIS in differentiated thyroid cancer, compared with normal thyroid tissue. DATA SOURCES: PUBMED, Sinomed, CNKI, Wanfang and VIP were searched for relevant case-control studies up to now. STUDY SELECTION: Studies that concerning the qualitative expression NIS in DTC were included. DATA EXTRACTION: Working independently, authors used a standard form to extract data. For quality assessment, Newcastle-Ottawa Scale (NOS) were applied. DATA SYNTHESIS: Totally nine eligible studies included, involving 765 cases and 473 controls. The results revealed that the expression of NIS had a statistically increased in DTC, compared with controls (OddsRadio OR: 1.47, 95% CI: 1.12 to 1.94, Z=2.78, P=0.005). Since the existence of the significant heterogeneity, subgroup analysis and sensitivity analysis were performed and found that the heterogeneity came from the different criteria evaluate positive NIS expression (Liu 2008, Mu 2010) and the small simple size of the control group (Lin. J D2001). The heterogeneity disappeared or dropped to below 50% after remove these studies. CONCLUSION: Our study shows that the expression of NIS is significantly increased in DTC, which could help explain the reason for individual with a poor response to RAI therapy. In other word, the reduced iodide uptake in thyroid cancer may not caused by the decreased expression of NIS, function of NIS protein or its post-transcriptional translocation might be the point.
CONTEXT: As many studies proved that sodium iodide symporter (NIS) plays a key role in radioactive iodide (RAI) therapy of thyroid cancer, however, a growing number of studies suggests that part of differentiated thyroid carcinomas (DTC) with overexpression of NIS are insensitive to RAI well. OBJECTIVE: The aim of this meta-analysis is to assess the expression of NIS in differentiated thyroid cancer, compared with normal thyroid tissue. DATA SOURCES: PUBMED, Sinomed, CNKI, Wanfang and VIP were searched for relevant case-control studies up to now. STUDY SELECTION: Studies that concerning the qualitative expression NIS in DTC were included. DATA EXTRACTION: Working independently, authors used a standard form to extract data. For quality assessment, Newcastle-Ottawa Scale (NOS) were applied. DATA SYNTHESIS: Totally nine eligible studies included, involving 765 cases and 473 controls. The results revealed that the expression of NIS had a statistically increased in DTC, compared with controls (OddsRadio OR: 1.47, 95% CI: 1.12 to 1.94, Z=2.78, P=0.005). Since the existence of the significant heterogeneity, subgroup analysis and sensitivity analysis were performed and found that the heterogeneity came from the different criteria evaluate positive NIS expression (Liu 2008, Mu 2010) and the small simple size of the control group (Lin. J D2001). The heterogeneity disappeared or dropped to below 50% after remove these studies. CONCLUSION: Our study shows that the expression of NIS is significantly increased in DTC, which could help explain the reason for individual with a poor response to RAI therapy. In other word, the reduced iodide uptake in thyroid cancer may not caused by the decreased expression of NIS, function of NIS protein or its post-transcriptional translocation might be the point.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Elaine C Morari; Marjory A Marcello; Ana Carolina T Guilhen; Lucas L Cunha; Paulo Latuff; Fernando A Soares; José Vassallo; Laura S Ward Journal: Clin Endocrinol (Oxf) Date: 2011-08 Impact factor: 3.478
Authors: Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe Journal: J Cell Sci Date: 2009-08-25 Impact factor: 5.285
Authors: Xiao-Cheng Wu; Vivien W Chen; Brooke Steele; Steven Roffers; Judith B Klotz; Catherine N Correa; Susan E Carozza Journal: J Adolesc Health Date: 2003-06 Impact factor: 5.012
Authors: Alix L de Dieuleveult; Petra C Siemonsma; Jan B F van Erp; Anne-Marie Brouwer Journal: Front Aging Neurosci Date: 2017-03-28 Impact factor: 5.750
Authors: Sabine Wächter; Annette Wunderlich; Brandon H Greene; Silvia Roth; Moritz Elxnat; Sebastian A Fellinger; Frederik A Verburg; Markus Luster; Detlef K Bartsch; Pietro Di Fazio Journal: Int J Mol Sci Date: 2018-07-17 Impact factor: 5.923